The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries.
IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.
The IASLC mission is:
- to embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies;
- to provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public;
- to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.
The IASLC Journal
The Journal of Thoracic Oncology (JTO) is the IASLC's premier Journal. JTO emphasizes a multidisciplinary approach in the articles accepted for publication, and includes original research (clinical trials and translational or basic research), reviews and opinion pieces. Become a member of IASLC and receive a complimentary subscription to the Journal of Thoracic Oncology. Members can login to the IASLC Member Portal to access the Journal articles (Membership must be current.)
The core audience for the Journal includes those involved in the research and treatment of thoracic malignancies including, epidemiologists, medical oncologists, pulmonologists, radiation oncologists, thoracic surgeons, radiologists, pathologists and research scientists.
First published in January of 2006, the journal has grown from publishing 9 issues a year to publishing one issue each month, along with several supplements. In 2006 the journal received 285 submissions and published 183 with an acceptance rate of 57% and on average 29 days to first decision. In 2013 the JTO received 1301 manuscripts and 244 were published with an acceptance rate of 17% and on average 14 days to first decision. It currently has an impact factor of 4.473.
Meet the Editor
Alex A. Adjei, MD, PhD, FACP
Dr. Adjei is Professor of Oncology in the Department of Medicine at Mayo Clinic in Rochester, Minnesota.
The IASLC Board of Directors approved a new strategic plan for the organization on September 12, 2011. This ambitious plan was developed after a 6-month process that culminated in a Strategic Planning Retreat, September, 2011 in Denver, USA.
GOAL 1 - IASLC embraces the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
GOAL 2 - IASLC provides education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
Research and Science
GOAL 3—IASLC advances research and science towards reducing the burden of thoracic malignancies worldwide.
GOAL 4 - IASLC is committed to long-term, global growth in membership.
Professional Membership Association
GOAL 5 - IASLC values the work of its volunteer members, who advance the IASLC mission through active participation and effective leadership.
Charitable Giving and Philanthropic Relationships
GOAL 6 - IASLC solicits philanthropic funds to support its research and educational programs.
GOAL 7 - To accomplish its mission, the IASLC is committed to operational excellence and fiscal responsibility.